^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    4d
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=3, Completed, Peking University | Recruiting --> Completed | N=18 --> 3
    Trial completion • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    6d
    IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy (clinicaltrials.gov)
    P1, N=3, Terminated, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | N=36 --> 3 | Trial completion date: Oct 2026 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> Oct 2025; The collaborating party has adjusted its R&D strategy and terminated the study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    13d
    QUADvance: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=178, Recruiting, AvenCell Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    20d
    An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Peking University People's Hospital
    New P1 trial
    |
    CD19 (CD19 Molecule)
    20d
    A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Huashan Hospital
    New P1 trial
    22d
    CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (clinicaltrials.gov)
    P1, N=5, Terminated, Medical College of Wisconsin | N=24 --> 5 | Trial completion date: Jun 2026 --> Sep 2025 | Suspended --> Terminated; Low accrual
    Enrollment change • Trial completion date • Trial termination
    |
    CD20 positive
    |
    CAR-20/19-T Cells
    22d
    IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 positive
    26d
    Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 Trial. (PubMed, Blood Adv)
    Based on the promising risk-to-benefit ratio, evaluation of zamto-cel at DL2 is ongoing in pivotal Phase II clinical trials for patients with r/r aggressive B-NHL. This trial was registered at www.clinicaltrials.gov as #NCT03870945.
    P1 data • Journal • IO biomarker • First-in-human
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL7R (Interleukin 7 Receptor) • CD27 (CD27 Molecule)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    27d
    DALY II Japan/MB-CART2019.1 for DLBCL (clinicaltrials.gov)
    P2, N=31, Recruiting, Miltenyi Biomedicine GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    28d
    KT-US-499-0150: Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=247, Recruiting, Kite, A Gilead Company | Phase classification: P1 --> P1/2 | N=114 --> 247
    Phase classification • Enrollment change
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8) • CSF2 (Colony stimulating factor 2) • IL15 (Interleukin 15) • IL1R1 (Interleukin 1 receptor, type I) • IL7 (Interleukin 7)
    |
    cyclophosphamide • fludarabine IV • KITE-363
    29d
    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2037 --> Mar 2039
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    cyclophosphamide • fludarabine IV • MB-106
    1m
    ELEVATION: A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Shanghai AbelZeta Ltd. | Trial completion date: Dec 2027 --> Jun 2028 | Trial primary completion date: Oct 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)